EDTA chelation therapy in chronic degenerative disease.
A retrospective analysis of treatment results from 2870 patients, with various chronic degenerative and age-associated diseases, who were treated with di-sodium magnesium EDTA chelation therapy, suggests that the case against EDTA Chelation Therapy should be re-opened. Using qualitative but never-the-less standardized criteria for improvement, our analysis shows that EDTA Chelation Therapy resulted in "marked" improvement in 76.89% and "good" improvement in 16.56% of patients with ischemic heart disease; also, "marked" improvement in 91% and "good" improvement in 7.6% of patients with peripheral vascular disease and intermittent claudication. In a group of patients with cerebro-vascular and other degenerative cerebral diseases, 24% had "marked" improvement, and 30% had "good" improvement. Of four patients with scleroderma, three had "marked" improvement and one had "good" improvement. Seventy-five percent of all of the patients had "marked" improvement in "geriatric symptomatology of vascular origin". The authors recommend renewed study of EDTA Chelation Therapy. The possibility of a "tomato effect", i.e., a drug which works, but the majority of physicians believe that it doesn't work, needs to be ruled out. A favorable climate needs to be created, in which FDA-approved studies of its usefulness in treating peripheral vascular disease can take place.
Olszewer
E
E
Hyperbaric Oxygen Clinic, Sao Paulo, Brazil.
Carter
J P
JP
D000818:Animals; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002908:Chronic Disease; D003327:Coronary Disease / Q000188:drug therapy*; D003704:Dementia / Q000188:drug therapy*; D004492:Edetic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D012189:Retrospective Studies; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D014652:Vascular Diseases / Q000188:drug therapy*
D004492:Edetic Acid